Celldex Therapeutics - Recruiting 18 years or older. - A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, GPNMB Over-Expressing, Triple Negative Breast Cancer. (The METRIC Study).
Celgene Corporation - Recruiting 18 years or older. - A Phase 2/3, Multi-center, Open-label, Randomized Study of Weekly Nab-paclitaxel in Combination With Gemcitabine or Carboplatin, Compared to the Combination of Gemcitabine and Carboplatin, as First-line Treatment in Female Subjects With ER, PgR, and HER2 Negative (Triple Negative) Metastatic Breast Cancer.
nab-Paclitaxel 125 mg/m2 plus carboplatin AUC 2 in triple negative metastatic breast cancer (TNMBC) subjects; Carboplatin AUC 2; gemcitabine 1000 mg
Calithera Biosciences, Inc - Recruiting 18 years or older. - A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Advanced and/or Treatment-Refractory Solid Tumors.
National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older. - A Phase I Study With an Expansion Cohort of the PARP Inhibitor AZD2281 Combined With Carboplatin in BRCA1/2 Familial Breast and Ovarian Cancer and Sporadic Triple Negative Breast and Ovarian Cancer.
The Methodist Hospital System - Recruiting 18 years or older. - Neoadjuvant Phase II Study Of Everolimus Plus Cisplatin In Triple Negative Breast Cancer Patients With Residual Disease After Standard Chemotherapy.
AstraZeneca - Recruiting 18 years or older. - A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD8186 in Patients With Advanced Castrate-resistant Prostate Cancer (CRPC), Squamous Non-Small Cell Lung Cancer (sqNSCLC), Triple Negative Breast Cancer (TNBC) and Patients With Known PTEN-deficient Advanced Solid Malignancies, With Expansion to Assess the Pharmacodynamic Activity of AZD8186 Within Prospectively-validated PTEN Deficient Tumours.
Synta Pharmaceuticals Corp. - Recruiting 18 years or older. - An Open Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib(STA-9090) Monotherapy in Women With Previously Untreated Metastatic HER2 Positive or Triple Negative Breast Cancer.
Vanderbilt-Ingram Cancer Center - Recruiting 18 years or older. - A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer.
cisplatin; laboratory biomarker analysis; pharmacological study; dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI; GDC -0941
Dana-Farber Cancer Institute - Recruiting 18 years or older. - Phase I Study of the Oral PI3kinase Inhibitor BKM120 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or Recurrent High Grade Serous Ovarian Cancer.
Dana-Farber Cancer Institute - Recruiting 18 years or older. - Phase II Study of Combination Ruxolitinib (INCB018242) With Preoperative Chemotherapy for Triple Negative Inflammatory Breast Cancer Following Completion of a Phase I Combination Study in Recurrent/Metastatic Breast Cancer.
Dana-Farber Cancer Institute - Recruiting 18 years or older. - A Randomized Phase II Study of Preoperative Cisplatin Versus Paclitaxel in Patients With Triple Negative Breast Cancer Without Germline BRCA Mutations: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker.
Cisplatin; Paclitaxel; Pre- and Post-chemotherapy clinical diagnostic tissue
Novartis - Recruiting 18 years or older. - A Phase II Multi-center, Open-label, Neoadjuvant, Randomized Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer.
AbbVie - Recruiting 18 years or older. - A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating Safety and Efficacy of the Addition of Veliparib Plus Carboplatin Versus the Addition of Carboplatin to Standard Neoadjuvant Chemotherapy Versus Standard Neoadjuvant Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer (TNBC).
Thomas Jefferson University - Recruiting 18 years or older. - An Adaptive, Randomized Phase II Trial to Determine Pathologic Complete Response With the Addition of Carboplatin With and Without Veliparib to Standard Chemotherapy in the Neoadjuvant Treatment of Triple-Negative Breast Cancer.
Medivation, Inc. - Recruiting 18 years or older. - A Phase 2, Single Arm, Open Label, Multicenter Study of the Clinical Activity and Safety of Enzalutamide in Patients With Advanced, Androgen Receptor Positive, Triple Negative Breast Cancer.
University of Washington - Recruiting 18 years or older. - Phase I Study of ABT-888 in Combination With Cisplatin and Vinorelbine for Patients With Advanced Triple Negative Breast Cancer and/or BRCA-Mutation Associated Breast Cancer.
veliparib; cisplatin; vinorelbine tartrate; laboratory biomarker analysis; pharmacological study
National Cancer Institute (NCI) - Recruiting 18 years or older. - A Phase 1 Study With Dose Expansion of Dinaciclib (SCH 727965) in Combination With Epirubicin in Patients With Metastatic Triple Negative Breast Cancer.
Chinese Academy of Medical Sciences - Recruiting 18 years to 70 years. - Phase II Study of Capecitabine and Cisplatin in Anthracycline and Taxanes-pretreated Metastatic Triple Negative Breast Cancer Patients.
China Breast Cancer Clinical Study Group - Recruiting 18 years to 70 years. - A Prospective, Randomized, Open, Multi-center Phase III Clinical Study Comparing Efficacy and Safety of Sequential T-FEC and TX-XEC as Post-operative Adjuvant Chemotherapy Options for the Treatment of Triple-negative Breast Cancer.
Fluorouracil/epirubicin/cyclophosphamide following Docetaxel; Docetaxel/capecitabine followed by XEC